Írland - enska - HPRA (Health Products Regulatory Authority)

teva b.v. - dasatinib - film-coated tablet - 70 milligram(s) - dasatinib

Malta - enska - Medicines Authority

synthon bv microweg 22, 6545 cm nijmegen, netherlands - dasatinib - film-coated tablet - dasatinib 20 mg - antineoplastic agents

Malta - enska - Medicines Authority

synthon bv microweg 22, 6545 cm nijmegen, netherlands - dasatinib - film-coated tablet - dasatinib 50 mg - antineoplastic agents

Malta - enska - Medicines Authority

synthon bv microweg 22, 6545 cm nijmegen, netherlands - dasatinib - film-coated tablet - dasatinib 70 mg - antineoplastic agents

Malta - enska - Medicines Authority

synthon bv microweg 22, 6545 cm nijmegen, netherlands - dasatinib - film-coated tablet - dasatinib 80 mg - antineoplastic agents

Malta - enska - Medicines Authority

synthon bv microweg 22, 6545 cm nijmegen, netherlands - dasatinib - film-coated tablet - dasatinib 100 mg - antineoplastic agents

Malta - enska - Medicines Authority

synthon bv microweg 22, 6545 cm nijmegen, netherlands - dasatinib - film-coated tablet - dasatinib 140 mg - antineoplastic agents

Ísrael - enska - Ministry of Health

bristol, myers squibb (israel) limited, israel - dasatinib - film coated tablets - dasatinib 100 mg - dasatinib - dasatinib - treatment of adult patients with : * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - dasatinib propylene glycol, quantity: 116 mg (equivalent: dasatinib, qty 100 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; hydrogenated castor oil; lactose; hypromellose; croscarmellose sodium; titanium dioxide; triacetin; silicon dioxide - reddy's-dasatinib is indicated for the treatment of adults aged 18 years or over with:,- newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. - philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,reddy's-dasatinib is indicated for the treatment of paediatric patients with:,- newly diagnosed ph+ all in combination with chemotherapy.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - dasatinib propylene glycol, quantity: 58 mg (equivalent: dasatinib, qty 50 mg) - tablet, film coated - excipient ingredients: titanium dioxide; silicon dioxide; lactose; microcrystalline cellulose; hydrogenated castor oil; magnesium stearate; croscarmellose sodium; hypromellose; triacetin - reddy's-dasatinib is indicated for the treatment of adults aged 18 years or over with:,- newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. - philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,reddy's-dasatinib is indicated for the treatment of paediatric patients with:,- newly diagnosed ph+ all in combination with chemotherapy.